These results indicated that 11C-l-1MTrp PET/CT could visually, quantitatively and spatiotemporally track the dynamic IDO1 expression in MLNs associated with immunotherapeutic efficacy and reveal the cancer-immune set point in individuals treated with IDO1 blockade-containing combinatorial immunotherapy. Here, IDO1 is linked to cancer.